Clinical Outcomes Of Cataract Surgeries Using A Next Generation Extended Depth Of Focus Intraocular Lens : A Real World Study

The TECNIS PureSee™ intraocular lens (IOL) is a purely refractive extended depth of focus (EDOF) IOL based on a continuous change in power. This study investigates the real-world clinical outcomes of cataract surgeries using the PureSee™ IOL.

This is a single-center, retrospective cohort study using medical chart review performed at Yonsei University College of Medicine.

57 patients who received cataract surgery with PureSee™ IOL implantation for senile cataract between September 2023 through December 2023 at Yonsei University College of Medicine by a single surgeon were retrospectively enrolled. Distal, intermediate, and near visual acuity (VA), defocus curves, and patient satisfaction surveys were collected at postoperative 3 months.

At postoperative 3 months, there were significant improvements in the mean logMAR uncorrected distance VA (from 0.39 ± 0.27 to 0.08 ± 0.12, p < 0.01) and logMAR corrected distance VA (from 0.16 ± 0.18 to 0.03 ± 0.08, p < 0.01). Defocus curves showed a <0.2 logMAR range between +0.70 to -1.30 diopters. Uncorrected near and intermediate VA were 0.22 ± 0.10 and 0.09 ± 0.07, respectively. Regarding patient satisfaction, only a minimal percentage reported moderate halo (16%), glare (24%), and starburst (8%), and none of the patients reported severe visual discomfort. The majority of patients (100%, 100%, and 88%) reported gaining spectacle independence for distance, intermediate, and near vision, respectively.

Patients who underwent cataract surgery with the PureSee™ IOL demonstrated good uncorrected far and intermediate vision, with functional near vision at the three-month postoperative assessment. None of the patients reported severe dysphotopsia. These findings underscore the PureSee™ IOL as a viable treatment option for cataract patients seeking enhanced intermediate vision without compromising visual quality.